Fig. 5From: Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settingsPlots of HR of PFS vs. HR of OS by study sample size regression line. Each trial is represented by a bubble whose radius is proportional to the trial sample sizeBack to article page